Cargando…

Alzheimer's disease therapeutic research: the path forward

The field of Alzheimer's disease therapeutic research seems poised to bring to clinic the next generation of treatments, moving beyond symptomatic benefits to modification of the underlying neurobiology of the disease. But a series of recent trials has had disappointingly negative results that...

Descripción completa

Detalles Bibliográficos
Autor principal: Aisen, Paul S
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2719107/
https://www.ncbi.nlm.nih.gov/pubmed/19674435
http://dx.doi.org/10.1186/alzrt2
_version_ 1782170054750633984
author Aisen, Paul S
author_facet Aisen, Paul S
author_sort Aisen, Paul S
collection PubMed
description The field of Alzheimer's disease therapeutic research seems poised to bring to clinic the next generation of treatments, moving beyond symptomatic benefits to modification of the underlying neurobiology of the disease. But a series of recent trials has had disappointingly negative results that raise questions about our drug development strategies. Consideration of ongoing programs demonstrates difficult pitfalls. But a clear path forward is emerging. Successful strategies will utilize newly available tools to reconsider issues of diagnosis, assessment and analysis, facilitating the study of new treatments at early stages in the disease process at which they are most likely to yield major clinical benefits.
format Text
id pubmed-2719107
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-27191072009-08-03 Alzheimer's disease therapeutic research: the path forward Aisen, Paul S Alzheimers Res Ther Commentary The field of Alzheimer's disease therapeutic research seems poised to bring to clinic the next generation of treatments, moving beyond symptomatic benefits to modification of the underlying neurobiology of the disease. But a series of recent trials has had disappointingly negative results that raise questions about our drug development strategies. Consideration of ongoing programs demonstrates difficult pitfalls. But a clear path forward is emerging. Successful strategies will utilize newly available tools to reconsider issues of diagnosis, assessment and analysis, facilitating the study of new treatments at early stages in the disease process at which they are most likely to yield major clinical benefits. BioMed Central 2009-07-09 /pmc/articles/PMC2719107/ /pubmed/19674435 http://dx.doi.org/10.1186/alzrt2 Text en Copyright © 2009 BioMed Central Ltd
spellingShingle Commentary
Aisen, Paul S
Alzheimer's disease therapeutic research: the path forward
title Alzheimer's disease therapeutic research: the path forward
title_full Alzheimer's disease therapeutic research: the path forward
title_fullStr Alzheimer's disease therapeutic research: the path forward
title_full_unstemmed Alzheimer's disease therapeutic research: the path forward
title_short Alzheimer's disease therapeutic research: the path forward
title_sort alzheimer's disease therapeutic research: the path forward
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2719107/
https://www.ncbi.nlm.nih.gov/pubmed/19674435
http://dx.doi.org/10.1186/alzrt2
work_keys_str_mv AT aisenpauls alzheimersdiseasetherapeuticresearchthepathforward